Overview


Generative AI in personalized medicine refers to the use of artificial intelligence, particularly generative models, to analyze and generate medical information and insights tailored to individual patients. This field leverages advanced machine learning techniques to process large datasets and generate patient-specific recommendations, treatments, or predictions. Generative AI can analyze a patient's medical record, including genetic information, imaging data, lab results, lifestyle factors, etc. It can identify patterns, correlations, and potential risk factors. Generative models can help discover new drugs or drug compounds by simulating molecular structures and predicting their potential efficacy. Based on a patient's unique genetic makeup, lifestyle, and medical history, generative AI can suggest personalized treatment plans. For instance, it can help determine the most effective dosage of a drug or recommend alternative therapies. Moreover, generative AI can assist in medical imaging analysis. It can help identify anomalies, lesions, or tumors in radiological images like X-rays, MRIs, and CT scans.

Generative AI is making significant advancements in optimizing patient outcomes, and its deployment models play a crucial role in its accessibility and effectiveness. In an on-premise deployment model, the generative AI system operates within the confines of a local healthcare facility. This setup provides more control over data security and compliance, which is important in safeguarding sensitive patient information. On the other hand, the cloud-based deployment of generative AI brings about unparalleled scalability and accessibility. By exploiting the power of cloud computing, healthcare institutions can tap into vast computational resources, enabling real-time analysis of vast datasets and rapidly generating personalized treatment recommendations.

FutureWise Market Research has published a report that provides an insightful analysis generative AI in personalized medicine market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts generative AI in personalized medicine market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Butterfly Network
  • Deep Genomics
  • Google LLC
  • IBM Watson Health
  • Microsoft Corporation
  • Aidoc
  • Insilico Medicine
  • PathAI
  • Tencent Holdings Ltd.
  • Neuralink Corporation
  • Johnson & Johnson

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Generative AI in Personalized Medicine Market:

  • In April 2023, Microsoft Azure Health Services teamed up with CueZen to revolutionize the healthcare industry. The partnership aims to lead CueZen's generative AI for healthcare and leverage Microsoft Azure's cloud services to provide their healthcare clients with personalized patient involvement care, particularly in generative AI in personalized medicines. This collaboration marks a significant step in tailoring treatments to individual patient needs.

The increasing prevalence of generative AI's proficiency in processing extensive patient data enables the creation of intricately tailored treatment plans. AI-driven algorithms may formulate precision-guided therapies by determining subtle nuances within medical histories, genetic profiles, and lifestyle factors. This heightened level of personalization not only enhances treatment efficacy but also mitigates the often costly and time-consuming process of trial-and-error in healthcare interventions. Patients stand to benefit significantly from treatments that are finely calibrated to their unique physiological makeup, ultimately leading to improved outcomes and a higher quality of care. Additionally, generative AI revolutionizes drug development by swiftly analyzing chemical compositions, biological data, and clinical trial results. This expedites the process, potentially culminating in the production of highly specialized drugs precisely attuned to specific medical needs. Thus driving the growth of the market over the forecast period. Moreover, cost efficiency is important in AI-driven models to that streamline healthcare processes, notably limiting expenses associated with unsuccessful drug trials. By swiftly identifying promising candidates and eliminating less viable options, Generative AI accelerates innovation and significantly economizes the resource-intensive journey of drug discovery and development. This holds the potential to make cutting-edge treatments more accessible and affordable for patients and further boosts the market expansion. However, handling sensitive patient information poses a significant hindrance, demanding stringent privacy and security measures. Achieving compliance with the intricate web of data protection regulations is a formidable task, given the highly sensitive nature of healthcare data. Also, the evolving landscape of personalized medicine worsens the problem. The absence of standardized protocols for integrating generative AI might introduce a degree of unpredictability in approaches and outcomes. This variability hinders seamless implementation and could lead to inconsistencies in treatment strategies, highlighting the need for cohesive standards in this developing region. Thus impeding the growth of the market.

By Personalized Medicine Therapeutics

  • Pharmaceutical
  • Genomic Medicine
  • Devices

By Deployment Model

  • On-premise
  • Cloud Based

By End-User

  • Hospitals and Clinics
  • Clinical Research
  • Healthcare Organizations
  • Diagnostic Centers

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is attributed to factors including the rapid adoption of artificial intelligence-based solutions by the medical sector, well-established healthcare infrastructure, rise in high R&D spending, technological advancements, growing use of medical imaging and analysis, and high adoption rate of technology in the U.S. is expected to accelerate to the market growth. In addition, government initiatives and private investments that promote the adoption of generative AI solutions for the growth of the medical field act as a growth factor for the market in North America. Also, the presence of key players, strategic initiatives, and product launches are also propelling the growth of the market over the forecast period. For instance, in June 2023, the Center for Precision Health and Artificial Intelligence announced the launch of “Dartmouth.” It is set to improve the quality and efficiency of precision medicines and health outcomes by doing interdisciplinary research in artificial intelligence and biomedical data.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Generative AI in Personalized Medicine Market By Personalized Medicine Therapeutics, By Deployment Model, By End-User, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1 Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3.Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Generative AI in Personalized Medicine Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Generative AI in Personalized Medicine Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Generative AI in Personalized Medicine Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Generative AI in Personalized Medicine Market, By Personalized Medicine Therapeutics Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Pharmaceutical
      2. Genomic Medicine
      3. Devices
  • 8.  Generative AI in Personalized Medicine Market, By Deployment Model Historical Analysis and Forecast 2024-2032 (USD Million)
      1. On-premise
      2. Cloud Based
  • 9.  Generative AI in Personalized Medicine Market, By End-User Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Hospitals and Clinics
      2. Clinical Research
      3. Healthcare Organizations
      4. Diagnostic Centers
  • 10.  North America Generative AI in Personalized Medicine Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.  Latin America Generative AI in Personalized Medicine Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.  Europe Generative AI in Personalized Medicine Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.  Asia Pacific Generative AI in Personalized Medicine Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032  

  • 14.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Butterfly Network
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Deep Genomics
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Google LLC
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. IBM Watson Health
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Microsoft Corporation
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Aidoc
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Insilico Medicine
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. PathAI
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Tencent Holdings Ltd.
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Neuralink Corporation
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Johnson & Johnson
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           12.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.  FutureWise SME Key Takeaway Points for Client
    •    

Partner

Our Clients